SCHEDULE 13D/A: Polaris Funds and Terrance McGuire Amend Tectonic Therapeutic Stake Disclosure Following Share Dilution

Polaris Partners and affiliated entities, including director Terrance McGuire, have filed an amended Schedule 13D for Tectonic Therapeutic, Inc., updating their beneficial ownership percentage due to dilution from the Issuer's recent private placement.

Summary

• This document is Amendment No. 1 to the Schedule 13D originally filed by the Reporting Persons with the SEC on June 25, 2024.
• The primary purpose of this amendment is to update the aggregate percentage of Common Stock owned by the Reporting Persons in Tectonic Therapeutic, Inc. due to dilution.
• The dilution occurred because Tectonic Therapeutic, Inc. sold additional shares of its Common Stock, resulting in a decrease of over one percent (1%) in the aggregate ownership reported by the Reporting Persons.
• As of the filing, Terrance McGuire beneficially owns 1,157,977 shares, representing 6.3% of the Common Stock, which includes holdings by PFC I (20,262 shares), PFC II (64,652 shares), and PP IX (1,073,063 shares).
• Polaris Partners IX, L.P. and Polaris Partners GP IX, L.L.C. each beneficially own 1,073,063 shares, representing 5.8% of the Common Stock.
• Polaris Founders Capital Fund I, L.P. and Polaris Founders Capital Fund Management Co. I, L.L.C. each beneficially own 20,262 shares, representing 0.1% of the Common Stock.
• Polaris Founders Capital Fund II, L.P. and Polaris Founders Capital Fund Management Co. II, L.L.C. each beneficially own 64,652 shares, representing 0.4% of the Common Stock.
• Jonathan Flint beneficially owns 84,914 shares, representing 0.5% of the Common Stock, comprising holdings by PFC I (20,262 shares) and PFC II (64,652 shares).
• The percentage ownership calculations are based on a total of 18,442,154 shares of Common Stock outstanding, which includes 14,752,689 shares outstanding as of November 1, 2024, and 3,689,465 shares sold in a private placement.

Sentiment

Score: 6

Explanation: The filing itself is a neutral regulatory update. While it notes dilution for the reporting persons, the underlying event (private placement) is a positive for the company as it represents a capital raise. The reporting persons' stated intent to potentially acquire or dispose of shares is standard language for a 13D and doesn't inherently signal strong negative sentiment.

Positives

• The Issuer (Tectonic Therapeutic, Inc.) successfully completed a private placement, selling 3,689,465 shares of Common Stock, which indicates a capital raise for the company.

Negatives

• The Reporting Persons' aggregate beneficial ownership percentage in Tectonic Therapeutic, Inc. decreased by over 1% due to dilution from the Issuer's sale of additional shares.

Risks

• The Reporting Persons reserve the right to dispose of some or all of their shares of Common Stock or other securities of the Issuer at any time, which could include open market or private transactions, block sales, or pursuant to Rule 10b5-1 programs, potentially leading to future selling pressure on the stock.

Future Outlook

The Reporting Persons intend to continuously review their investment in Tectonic Therapeutic, Inc. based on various factors including the Issuer's business, financial condition, results of operations, prospects, general economic and industry conditions, and the securities markets. They explicitly reserve the right to acquire or dispose of additional shares or other securities of the Issuer at any time, through various transaction types (e.g., open market, private transactions, block sales, Rule 10b5-1 programs), and to change their investment purpose or plans.

Industry Context

This filing is a routine disclosure of changes in beneficial ownership due to a capital raise by the Issuer. It does not provide specific insights into broader industry trends beyond the fact that Tectonic Therapeutic, Inc. is raising capital, which is a common activity for companies, particularly in the biotechnology or pharmaceutical sectors, to fund research, development, and operational expenses.

Stakeholder Impact

• Shareholders: Existing shareholders experienced dilution due to the private placement, which increased the total number of outstanding shares. However, the capital raise provides Tectonic Therapeutic with additional funds, which could support its operations and strategic initiatives.
• Company (Tectonic Therapeutic, Inc.): Benefited from a capital raise through the private placement, securing additional funding for its operations.

Next Steps

• Reporting Persons will continue to review their investment in Tectonic Therapeutic, Inc. based on various factors.
• Reporting Persons may acquire additional shares or other securities of the Issuer in the future.
• Reporting Persons may dispose of some or all of their shares or other securities of the Issuer in the future.
• Reporting Persons may review or reconsider their position, change their investment purpose, or formulate and implement new plans or proposals regarding their investment.

Key Dates

Keywords

Tectonic Therapeutic, SEC filing, Schedule 13D, beneficial ownership, shareholding, Polaris Partners, Terrance McGuire, Jonathan Flint, private placement, dilution, common stock